Dinesh V. Patel

Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.